导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.59% | 2827/4530 |
| 近一周 | -2.03% | 3743/5165 |
| 近一月 | -4.29% | 1581/5119 |
| 近一季 | -3.03% | 1308/4951 |
| 近半年 | -6.19% | 3086/4673 |
| 近一年 | -1.13% | 2637/4194 |
| 近两年 | 32.85% | 2056/2824 |
| 近三年 | 18.72% | 1436/2141 |
| 成立以来 | 156.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.16% 1721/4961 |
-0.12% 3251/5312 |
- - |
- - |
| 2025 | 12.45% 2691/4813 |
2.22% 1433/3635 |
-2.85% 3386/4076 |
11.33% 3179/4524 |
1.72% 1250/4813 |
| 2024 | 17.01% 740/3463 |
5.53% 352/2808 |
0.31% 634/3014 |
15.25% 1774/3129 |
-4.09% 2434/3463 |
| 2023 | -0.97% 486/2656 |
10.41% 367/2280 |
-0.15% 365/2385 |
-3.55% 950/2515 |
-6.86% 1946/2655 |
| 2022 | -19.79% 900/2207 |
-11.49% 520/1919 |
0.29% 1564/2016 |
-13.28% 873/2113 |
4.19% 578/2208 |
| 2021 | -7.00% 1024/1822 |
1.32% 258/1255 |
-4.70% 1264/1330 |
-5.06% 772/1466 |
1.44% 932/1822 |
| 2020 | 20.32% 721/1250 |
-14.54% 968/1028 |
13.52% 613/1067 |
9.13% 670/1164 |
13.64% 344/1184 |
| 2019 | 53.97% 77/1092 |
37.73% 73/754 |
-0.27% 245/804 |
0.70% 481/850 |
11.31% 66/918 |
| 2018 | -28.74% 443/834 |
- - |
- - |
- - |
-11.54% 314/691 |
| 2017 | 32.47% 47/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.63% 251/605 |
- - |
- - |
- - |
- - |
| 2015 | 15.34% 141/575 |
- - |
- - |
- - |
- - |
| 2014 | 45.96% 105/237 |
- - |
- - |
- - |
- - |
| 2013 | -2.82% 73/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.94% 81/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 交银深证300价值ETF VS. 长安沪深300非周期A(740101) |